Sandoz Group AG

“Sandoz holds the best pure-play biosimilars portfolio globally and is executing a genuine transformation from a commoditized generics base toward a structurally higher-return biosimilar business — but the current price of CHF 67.76 already reflects that ambition, offering no margin of safety for a business still generating blended ROIC of 6–7%, with an unresolved antitrust liability, a management team with less than three years of independent operating history, and a generics division in structural decline. The bull case is credible but priced in; the right action is to track for a pullback toward CHF 48–54 where the biosimilar optionality is available at a fair price for the blended enterprise.”